These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10658943)

  • 21. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
    Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
    J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects.
    Struck J; Muck P; Trübger D; Handrock R; Weidinger G; Dendorfer A; Dodt C
    J Hypertens; 2002 Jun; 20(6):1143-9. PubMed ID: 12023684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
    de Gasparo M; Hess P; Nuesslein-Hildesheim B; Bruneval P; Clozel JP
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):151-8. PubMed ID: 11967807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
    Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
    Yasunari K; Maeda K; Watanabe T; Nakamura M; Yoshikawa J; Asada A
    J Am Coll Cardiol; 2004 Jun; 43(11):2116-23. PubMed ID: 15172423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of nisoldipine and/or enalapril on left ventricular function and exercise capacity in patients with recent anterior myocardial infarction and mild cardiac dysfunction.
    Romano M; Cardei S; de Arcangelis E; Monteforte I; Capaldo M; Muto P; Marchegiano R; Kilama MO; Condorelli M
    Am Heart J; 1997 Mar; 133(3):268-72. PubMed ID: 9060793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension.
    Petersen JR; Drabaek H; Gleerup G; Mehlsen J; Petersen LJ; Winther K
    Angiology; 1996 Mar; 47(3):233-40. PubMed ID: 8638865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment.
    Mizuta Y; Kai H; Mizoguchi M; Osada K; Tahara N; Nakaura H; Kuwahara F; Imaizumi T;
    Hypertens Res; 2008 Oct; 31(10):1835-42. PubMed ID: 19015589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril.
    Der Sarkissian S; Marchand EL; Duguay D; Hamet P; deBlois D
    Cardiovasc Res; 2003 Mar; 57(3):775-83. PubMed ID: 12618239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
    Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
    J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance of blood pressure control and left ventricular performance with small doses of enalapril.
    González-Juanatey JR; Reino AP; García-Acuña JM; González-Juanatey C; Valdes L; de la Peña MG; Cabezas-Cerrato J
    Am J Cardiol; 1999 Mar; 83(5):719-23. PubMed ID: 10080425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of type 2 diabetes mellitus on left ventricular diastolic function in patients with essential hypertension: evaluation by volume-time curve of cardiac magnetic resonance.
    Yan WF; Gao Y; Zhang Y; Guo YK; Wang J; Jiang L; Li Y; Yang ZG
    Cardiovasc Diabetol; 2021 Mar; 20(1):73. PubMed ID: 33766020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
    Stergiou GS; Skeva II; Baibas NM; Roussias LG; Kalkana CB; Achimastos AD; Mountokalakis TD
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):937-41. PubMed ID: 10836730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.
    Cuspidi C; Muiesan ML; Valagussa L; Salvetti M; Di Biagio C; Agabiti-Rosei E; Magnani B; Zanchetti A;
    J Hypertens; 2002 Nov; 20(11):2293-300. PubMed ID: 12409969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
    Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.